Introducing Envision Pharma Group

Andrea Cifelli, Global Operations Lead

May 2019
Who are we?
DEVELOPMENT OF ENVISION PHARMA

- Envision incorporated
- First Datavision client established
- Sale of Envision to UBC
- Realignment for growth, including formation of three Scientific Solutions divisions
- Participation of Express Scripts in acquisition of Medco
- Medco purchased by Express Scripts
- Owner ProScribe (Australia)
- ProScribe (Australia) re-established
- Alligent Group
- Ardian invests in Envision
- Curo
- Opened office in Tokyo, Japan
- Touch

The Envision Pharma Group ‘Family’
A global leader in medical communications

700+ employees 12 offices 4 continents

USA
Glastonbury CT
Madison/Stirling NJ
Philadelphia PA
Southport CT

UK
Bishop’s Stortford
Hammersmith
Horsham
Wilmslow

SERBIA
Sombor

JAPAN
Tokyo

AUSTRALIA
Sydney

5
We partner with companies of all types

24% Big Pharma
55% Medium-sized
21% Small/start-ups

20% privately owned
80% public

Client headquarters located across the globe

77 in North America
33 in Europe
12 in Asia
1 in Australia
Scientific excellence is at our core...

- 250+ highly-educated writers
- Expertise in >30 key therapy areas

- **RETENTION OF STAFF**: 94% staff retention
- **HIGHLY EDUCATED**: 90% have advanced degrees
- **HIGHLY EXPERIENCED**: 50% with over 5 years’ experience
- **GLOBALLY LOCATED WRITERS**: 51% or writers non-US, 49% US based
- **CMPP CERTIFIED**: 50% of total but the majority of publications writers
- **COMPLIANCE TRAINED**: 100% of writers trained in pubs or medcomms compliance
- **90%**: 90% have advanced degrees
- **50%**: 50% with over 5 years’ experience
- **51%**: 51% or writers non-US, 49% US based

- **100%**: 100% staff retention
- **94%**: 94% staff retention
- **90%**: 90% staff retention
- **50%**: 50% staff retention
- **100%**: 100% staff retention
- **50%**: 50% staff retention
- **90%**: 90% staff retention
- **50%**: 50% staff retention
- **51%**: 51% staff retention
- **100%**: 100% staff retention
- **50%**: 50% staff retention
- **90%**: 90% staff retention
- **50%**: 50% staff retention
- **51%**: 51% staff retention
- **100%**: 100% staff retention
- **50%**: 50% staff retention
- **90%**: 90% staff retention
- **50%**: 50% staff retention
- **51%**: 51% staff retention
- **100%**: 100% staff retention
- **50%**: 50% staff retention
- **90%**: 90% staff retention
- **50%**: 50% staff retention
- **51%**: 51% staff retention
What do we do?
We provide...

Right content
Right person
Right channel
Right time
Publications support is a key Envision Pharma Group core competency...

- **Strategic publication planning**
- **Tactical implementation**
- **Publications writing**
- **Digital publications**

Proud contributors to advancing publications practices across the industry

- Authorship of the (new) GPP3 guidelines
- Authorship of the Global Publication Survey
- Directors and Chairs of Core Committees of ISMPP
- Presentation at ISMPP and Peer Review Congress
- ISPOR Task Force membership and abstract review panel
- Foundation of the Global Alliance of Publication Professionals
- Representing the Committee of Publication Ethics
- Publishing research on publication practices
...supported by industry-leading technology
...but we support clients from strategy to execution across all channels
Each year Envision...

ENGAGES WITH:

- MEDICAL/COMMERCIAL TEAMS: >2000
- SCIENTIFIC LEADERS: >2500
- MATERIALS/SUPPORT: >2000
- PUBLICATIONS: >2000
- SYMPOSIA: >200
- ADVISORY BOARDS: >200
- SLIDE DECKS: >150
- EXECUTES: >100

Congress Support
Envision the Patient: Powering Patient Voices

• Our dedicated team and a framework guiding all of Envision’s patient-centered programs

• Launched in 2017

• Driven in collaboration with external patient experts

• Working with clients and patient partners to build understanding and open up dialogue
PM Society: Events & Exhibitions Gold Award Winners
In a nutshell...
1.2 Response Durability and Survival Outcomes are Particularly Poor for Patients who are Refractory to Both a PI and an IMiD

1.2.1 Response durability and survival for patients with MM decreases with each line of therapy
- In a phase 3b prospective randomized trial, 130 patients with relapsed/RR MM treated with refamustine, 100 mg/m², or IFN-α + IFN-β demonstrated superior median PFS for the refamustine arm (HR 0.56, P < 0.001).
- In a retrospective study from Korea, median PFS was 13 months with IFN-α + IFN-β compared to 9 months with IFN-α alone (HR 1.47, P = 0.0065).

1.2.2 Patient with RRMM who are double-refractory have a median OS of less than 1 year
- In a retrospective study of 212 patients, median OS was 9 months in patients who were double-refractory to two prior lines of therapy (HR 1.03).

1.2.3 Rapid disease progression has also been observed in double-refractory patients with RRMM
- In a retrospective study of 59 patients, median PFS was 6.5 months in patients who were double-refractory to two prior lines of therapy.

1.2.4 Refractoriness to bortezomib and lenalidomide limits the treatment options available for patients leading to poor prognosis.
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals


Journal of Clinical Medicine 2018, 7, 541-553

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

Konsella Newton, David W. W. G. O’Rourke, Marta de la Bella, Guy De Bacquer, Lennart Edlund, Michele Ferras, Annick Georges, Frédéric Gély, Philippe Amann, Jon Brohan, Aimé Castro-Córdoba, René Cieus, Jacek W. Dzikowski, Johan De Sutter, Mirza Dib, Massoud Djalali, Andrea Egli, Elisa Friè, Dan Gatta, Nina Gutke, John Guo, Jean Huygen, Peter Hoogenraad, Ahlyshangi, L ruined, Sappe, Lehi, Ji, Hwan, David, Wongsade, Oksana Nikolayev, Raphael ogren, Andrew Pajak, Hans Poppen, Zeichl, Barbi, Maria, de, Johan Schuit, and Dorin Yolcu

J Cardiovasc Med 2018, 19, 430-438
Clinical trials: do the patients get the thanks they deserve?

Ethel R. Anthony P.
Envision Pharma Group, Horsley, UK

Abstract

Patient engagement in clinical trials is critical for the successful completion of studies. The impact of patient engagement on trial outcomes and participant retention is well-documented. However, the benefits of patient engagement are often not measured or reported. This can lead to an underestimation of the value of patient engagement in clinical trials. In this article, we review the benefits of patient engagement in clinical trials and discuss how to measure these benefits. We also provide recommendations for improving patient engagement in clinical trials. Patient engagement in clinical trials is critical for the successful completion of studies. The impact of patient engagement on trial outcomes and participant retention is well-documented. However, the benefits of patient engagement are often not measured or reported. This can lead to an underestimation of the value of patient engagement in clinical trials. In this article, we review the benefits of patient engagement in clinical trials and discuss how to measure these benefits. We also provide recommendations for improving patient engagement in clinical trials.

Methods

The methods used in this study were qualitative interviews with patient advocates and focus groups with patients. The qualitative interviews were conducted with a focus on understanding the experiences of patient advocates in engaging with clinical trials. The focus groups were conducted to understand the views of patients on patient engagement in clinical trials. The qualitative interviews and focus groups were analyzed using thematic analysis. The analysis involved coding the data and identifying themes. The themes were then synthesized to provide an overview of the experiences and views of patient advocates and patients on patient engagement in clinical trials.

Results

The results of the study showed that patient engagement in clinical trials is critical for the successful completion of studies. The impact of patient engagement on trial outcomes and participant retention is well-documented. However, the benefits of patient engagement are often not measured or reported. This can lead to an underestimation of the value of patient engagement in clinical trials. In this article, we review the benefits of patient engagement in clinical trials and discuss how to measure these benefits. We also provide recommendations for improving patient engagement in clinical trials.

Conclusions

Patient engagement in clinical trials is critical for the successful completion of studies. The impact of patient engagement on trial outcomes and participant retention is well-documented. However, the benefits of patient engagement are often not measured or reported. This can lead to an underestimation of the value of patient engagement in clinical trials. In this article, we review the benefits of patient engagement in clinical trials and discuss how to measure these benefits. We also provide recommendations for improving patient engagement in clinical trials.
Creative stuff

Immune Response Mechanisms with TKIs in Chronic Myeloid Leukaemia

Tuesday 17 April 2018
15:30-16:30
Anfield Convention Centre, Liverpool, UK

A LOOK AHEAD
The Next Chapter of Immuno-Oncology Research in Hematologic Malignancies

Satellite Symposium:
Thursday 22 June 2017

22nd Congress of the European Hemato-Oncology Association

22nd Congress of European Hematology Association
Cool stuff
What can we do for each other?
What we look for at entry level

- Postgraduate qualification (e.g. PhD)
- First degree + equivalent relevant research or industry experience

- Passion for communicating medical and scientific data
- Excellent attention to detail
- Ability to quickly pick up new information/concepts...
- ...and communicate a compelling story to different audiences
- Team player
Our Envision values

Together

Trust

Humility

Courage

Create value

Respect
Flexible training and development

• Ongoing recruitment

• Embedded in teams and supported by allocated mentor (and colleagues)

• Structured core induction plus flexible role-based training curriculum (ongoing professional development)

• Training via classroom, on-line, bespoke eLearning tool

• Flexible career development paths
Professional development options

Content Development Specialists
- Specialist writing focus
- Develop as expert advisors
- Mentor and support

Scientific Account and Team Leadership
- Scientific leadership of accounts/programs
- Line management of teams

Scientific Account Leadership
- Scientific leadership of accounts/programs
- Mentor and support

Senior Medical Writer
Medical Writer
Associate Medical Writer
Our Benefits
...and we have fun too!
Is this you?

• Postgraduate qualification (e.g. PhD) or
• First degree + equivalent relevant research or industry experience

Passion for communicating medical and scientific data

Excellent attention to detail

Ability to quickly pick up new information/concepts...

...and communicate a compelling story to different audiences

Team player